1 specialty the exception as telehealth continues to tumble

Going by private health-insurance data, national telehealth utilization dropped 12.5% this spring, slipping from 5.6% of claims in March to 4.9% in April.

This made for a three-month trend as recorded by Fair Health’s monthly regional telehealth tracker. The service showed declines of 5.1% in March vs. February and of 15.7% in February vs. January.

The falloff owes largely to the comeback of in-person doctor visits following telemedicine’s surge during the public health crisis brought on by COVID, Fair Health points out in a July 7 news release.

One corner of U.S. healthcare is bucking the trend: Virtual mental healthcare is still on the rise, growing from 57% of claims in March to 58.6% in April.

Also of interest, acute respiratory ailments increased in April as a percentage of telehealth claim lines nationally and in the Midwest and South.

“As the COVID-19 pandemic wanes, this suggests a return to non-COVID respiratory conditions, such as colds and bronchitis,” the nonprofit consumer group says.

“Also in April,” Fair Health notes, “general signs and symptoms joined the top five telehealth diagnoses in the West, again suggesting a return to more ‘ordinary,’ non-COVID conditions such as colds and stomach viruses.”

The findings are consistent with those from Trilliant, which recently reported U.S. telehealth sessions falling below 10 million in January for the first time since the spring of 2020.

Fair Health news release here, latest interactive tracking map here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.